Literature DB >> 31194038

A survival case of a young adult patient with ST-elevated myocardial infarction with high levels of lipoprotein(a).

Hiroaki Hiraiwa1, Ryota Morimoto1, Takahiro Okumura1, Yoshihito Arao1, Hideo Oishi1, Hiroo Kato1, Shogo Yamaguchi1, Tasuku Kuwayama1, Tomoaki Haga1, Tsuyoshi Yokoi1, Toru Kondo1, Naoki Watanabe2, Takayuki Mitsuda1, Kenji Fukaya1, Akinori Sawamura1, Akihito Tanaka1, Hideki Ishii1, Itsuro Morishima2, Hideyuki Tsuboi2, Toyoaki Murohara1.   

Abstract

A 23-year-old Japanese man presented to a nearby hospital with a complaint of chest pain. In terms of the risk factors for cardiovascular events, there were no abnormal findings in past medical examinations and no smoking history. The 12-lead electrocardiogram revealed ST-elevation in V1-V6, I, and aVL, and he was diagnosed with acute myocardial infarction. Emergency coronary angiography findings revealed total occlusion of the left main trunk and collateral vessels from the right coronary artery to the left anterior descending artery. He underwent emergency percutaneous coronary intervention and placement of drug-eluting stent under the support of venoarterial-extracorporeal membrane oxygenator (VA-ECMO). On day 8 after the onset, transthoracic echocardiography revealed that cardiac function improved with left ventricular ejection fraction from 10% to 20% and VA-ECMO was successfully removed. Alternatively, laboratory findings revealed abnormally high levels of serum lipoprotein(a) [Lp(a), 74 mg/dL] despite the normal levels of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride. In addition, computed tomography angiography revealed atherosclerosis and stenosis of internal and external carotid arteries, subclavian artery, and renal artery. The abnormally high levels of serum Lp(a) could influence systemic atherosclerosis as well as the onset of myocardial infarction in our young adult patient. <Learning objective: This was a rare survival case of a young adult patient with acute extensive myocardial infarction owing to plaque rupture of the left main trunk. Additionally, he had atherosclerosis of the whole body, including the carotid artery, subclavian artery, and renal artery. Blood test results revealed abnormally high levels of serum lipoprotein(a) [Lp(a)] despite the normal levels of low-density lipoprotein cholesterol. Lp(a) could strongly influence coronary atherosclerosis and myocardial infarction.>.

Entities:  

Keywords:  Atherosclerosis; Lipoprotein(a); ST-elevation myocardial infarction; Young adult

Year:  2019        PMID: 31194038      PMCID: PMC6546640          DOI: 10.1016/j.jccase.2019.02.004

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  10 in total

1.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

Review 2.  Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis.

Authors:  Arjun Deb; Noel M Caplice
Journal:  Clin Cardiol       Date:  2004-05       Impact factor: 2.882

3.  Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).

Authors:  Daniel Gaudet; Gerald F Watts; Jennifer G Robinson; Pascal Minini; William J Sasiela; Jay Edelberg; Michael J Louie; Frederick J Raal
Journal:  Am J Cardiol       Date:  2016-09-29       Impact factor: 2.778

4.  Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention.

Authors:  Hirokazu Konishi; Katsumi Miyauchi; Takatoshi Kasai; Shuta Tsuboi; Manabu Ogita; Ryo Naito; Eiryu Sai; Yoshifumi Fukushima; Yoshiteru Katoh; Iwao Okai; Hiroshi Tamura; Shinya Okazaki; Hiroyuki Daida
Journal:  Am J Cardiol       Date:  2014-10-29       Impact factor: 2.778

5.  Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.

Authors:  Paul J Nestel; Elizabeth H Barnes; Andrew M Tonkin; John Simes; Marion Fournier; Harvey D White; David M Colquhoun; Stefan Blankenberg; David R Sullivan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-03       Impact factor: 8.311

6.  Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction.

Authors:  Takayuki Mitsuda; Yusuke Uemura; Hideki Ishii; Kenji Takemoto; Tomohiro Uchikawa; Masayoshi Koyasu; Shinji Ishikawa; Ayako Miura; Ryo Imai; Satoshi Iwamiya; Yuta Ozaki; Tomohiro Kato; Rei Shibata; Masato Watarai; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2016-03-02       Impact factor: 2.037

7.  Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

Authors:  Amit V Khera; Brendan M Everett; Michael P Caulfield; Feras M Hantash; Jay Wohlgemuth; Paul M Ridker; Samia Mora
Journal:  Circulation       Date:  2013-11-17       Impact factor: 29.690

8.  Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

Authors:  John J Albers; April Slee; Kevin D O'Brien; Jennifer G Robinson; Moti L Kashyap; Peter O Kwiterovich; Ping Xu; Santica M Marcovina
Journal:  J Am Coll Cardiol       Date:  2013-08-21       Impact factor: 24.094

Review 9.  Management of residual risk after statin therapy.

Authors:  Christina Reith; Jane Armitage
Journal:  Atherosclerosis       Date:  2015-12-13       Impact factor: 5.162

10.  Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.

Authors:  Deepti Gurdasani; Barbara Sjouke; Sotirios Tsimikas; G Kees Hovingh; Robert N Luben; Nicholas W J Wainwright; Cristina Pomilla; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Manjinder S Sandhu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.